Dr. Mickle co-founded KemPharm Inc. in 2006 with the discovery of the company’s LAT® (Ligand Activated Therapy) prodrug technology. As President, Chief Executive Officer and Chairman of the Board he oversees KemPharm’s business and scientific strategy and is instrumental in the ongoing development of the company’s pipeline of proprietary prodrugs. Prior to founding KemPharm, Dr. Mickle served as Director of Drug Discovery and CMC at New River Pharmaceuticals where he was the principal inventor of Vyvanse®, a prodrug of amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD). Today, Vyvanse is the branded market share leader in the estimated $17 billion plus ADHD market. The success of Vyvanse along with a robust pipeline of prodrugs targeting ADHD, pain and thyroid dysfunctions, which Dr. Mickle was responsible for creating, led to New River Pharmaceuticals being acquired by Shire Pharmaceuticals, PLC for $2.6 billion. During his career, Dr. Mickle has been granted more than 80 US and EP (Europe) patents and has authored more than 100 patent applications US and worldwide, primarily focused on abuse-deterrent prodrugs in pain management and mental health, including multiple patents for prodrugs of hydrocodone, methylphenidate, and amphetamine. He is also the principal or secondary investigator on numerous published abstracts and scientific articles. Dr. Mickle received his Ph.D. degree from the University of Iowa and his B.A. degree from Simpson College.
Travis C. Mickle, Ph.D.
President, Chief Executive Officer and Chairman of the Board; Co-Founder
View more >>
As Chief Financial Officer, Secretary and Treasurer, Mr. Clifton is responsible for the company’s financial, operating and compliance activities. Mr. Clifton brings to KemPharm significant public company experience, along with expertise in managed care contracting and strategic leadership covering operations, compliance, investor relations and business development. Prior to joining KemPharm, Mr. Clifton served as the Chief Financial Officer, Secretary and Treasurer of The LGL Group, Inc., a publicly-held global producer of highly-engineered electronic components and services. Mr. Clifton also previously served as the Chief Financial Officer of a21, Inc., a publicly-held holding company with businesses in stock photography and the online retail and manufacture of framed art, as well as a variety of finance, medical cost analysis, and managed care provider contracting roles with Aetna, Inc. Mr. Clifton was an auditor with KPMG, LLP, and received his B.B.A. and M.B.A. from the University of North Florida. Mr. Clifton is a certified public accountant licensed by the State of Florida.
R. LaDuane Clifton, CPA
Chief Financial Officer, Secretary and Treasurer
View more >>
Mr. Pascoe has served as a director of KemPharm since January 2014 and as KemPharm’s executive chairman since November 2021. He served as lead independent director at KemPharm from November 2014 to November 2021. Mr. Pascoe served as the president and chief executive officer of Histogen Inc, a biologics company, from January 2019 to November 2021. From March 2013 to January 2019, Mr. Pascoe was the chief executive officer and a director of Apricus Biosciences, Inc., a specialty pharmaceutical company. From August 2008 to March 2013, Mr. Pascoe was the president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company. Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where he was most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc, a specialty pharmaceutical company. Mr. Pascoe received his B.S. degree from the United States Military Academy at West Point.
Richard W. Pascoe
Executive Chairman
View more >>

Press Contacts

Nichol Ochsner
VP, Investor Relations and Corporate Communications